Page last updated: 2024-11-13

sodium ethylxanthate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sex: The totality of characteristics of reproductive structure, functions, PHENOTYPE, and GENOTYPE, differentiating the MALE from the FEMALE organism. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23690437
CHEMBL ID3188975
SCHEMBL ID228666
MeSH IDM0308792

Synonyms (43)

Synonym
carbonodithioic acid, o-ethyl ester, sodium salt
sex
sodium o-ethyl carbonodithioate
sodium o-ethyl dithiocarbonate
140-90-9
ethylxanthic acid sodium salt
E0195
sodium ethylxanthate
sodium xanthogenate
sodium ethylxanthogenate
tox21_301765
cas-140-90-9
NCGC00256108-01
dtxcid9024801
dtxsid1044801 ,
3r5a3652vk ,
ec 205-440-9
carbonodithioic acid, o-ethyl ester, sodium salt (1:1)
unii-3r5a3652vk
einecs 205-440-9
SCHEMBL228666
AKOS025294486
RZFBEFUNINJXRQ-UHFFFAOYSA-M
sodium ethyl xanthate
CHEMBL3188975
sodium o-ethyl xanthate
xanthic acid, ethyl-, sodium salt
sodium ethyl xanthogenate
sodium xanthate
o-ethyl sodium dithiocarbonate
carbonic acid, dithio-, o-ethyl ester, sodium salt
ethylxanthic acid sodium salt, aldrichcpr
mfcd00068314
FT-0722813
Q6578729
sodium [ethyl hydroxy(carbonothioyl)]sulfanide
EN300-85510
sodium;ethoxymethanedithioate
D90455
CS-0445957
AS-80302
AKOS040768579
ethoxycarbothioylsulfanylsodium

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Behaviors considered to be safe are listed along with Center for Disease Control recommendations for the prevention of HIV transmission in health care settings."( Safer sex.
DeBrow, ME,
)
0.13
" Adverse effects with regard to bowel function and micturition were investigated, and graded 0-4 with increasing severity and impact on performance status, essentially according to the RTOG toxicity scoring system."( Adverse effects after radical external beam radiotherapy of localized prostatic adenocarcinoma using two-dimensional dose-planning and a limited field technique.
Häggman, M; Hansson, H; Holmberg, L; Ljung, G; Nilsson, S, 1996
)
0.29
" Commonly reported adverse events (AEs) were headache, flushing, dyspepsia, and rhinitis, which were generally mild to moderate."( Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment.
Feldman, RA; Gingell, C; Guay, AT; Hargreave, TB; Leriche, A; Price, DE; Steers, W; Wright, PJ, 2001
)
0.31
" Gender differentials in mortality in South Asia are explained followed by consideration of health, fertility, and women's status, and strategies needed to promote safe motherhood."( Safe motherhood in South Asia: current status and strategies for change.
Raza, B; Sathar, ZA, 1994
)
0.29
"The occurrence of adverse events (AEs) in care settings is a patient safety concern that has significant consequences across healthcare systems."( Adverse events associated with hospitalization or detected through the RAI-HC assessment among Canadian home care clients.
Baker, GR; Blais, R; Dill, D; Doran, D; Droppo, L; Foebel, A; Gruneir, A; Heckman, G; Hirdes, JP; Lacroix, H; Li, X; McIsaac, C; Mitchell, L; Nahm, SM; O'Beirne, M; Poss, JW; Qian, G; White, N; Yim, O, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" This paper discusses how physiological factors may influence the pharmacokinetic behaviour of inhaled organic solvent vapours, especially in relation to monitoring of biological exposure."( A simulation study of physiological factors affecting pharmacokinetic behaviour of organic solvent vapours.
Endoh, K; Johanson, G; Kaneko, T; Sato, A, 1991
)
0.28
" While gender-specific pharmacodynamic data are meager, evidence also supports the existence of sex-related differences."( Gender differences in human pharmacokinetics and pharmacodynamics.
Acosta, EP; Fletcher, CV; Strykowski, JM, 1994
)
0.29
" The data suggest that different pharmacodynamic responses are observed between premenopausal women and men."( Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants.
Bies, RR; Bigos, KL; Pollock, BG, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Clinical investigations have documented greater absorption and subsequent incorporation of iron into erythrocytes, and higher bioavailability of ethanol in females."( Gender differences in human pharmacokinetics and pharmacodynamics.
Acosta, EP; Fletcher, CV; Strykowski, JM, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" It is suggested that the lowest dosage of oral contraceptive pill be used with full understanding of adverse side effects and agreement to discontinue their use if complications arise."( Planning for sex, marriage, contraception, and pregnancy.
Boehm, FH; Christman, B; Graber, AL,
)
0.13
" It is proposed that mle interacts with a gene(s) on the X chromosome, which is not dosage compensated."( Maleless, a recessive autosomal mutant of Drosophila melanogaster that specifically kills male zygotes.
Fukunaga, A; Oishi, K; Tanaka, A, 1975
)
0.25
" The locus responsible for sulfoiduronate sulfatase deficiency in this X-linked mucopolysaccharidosis is therefore subjected to dosage compensation in females."( Mosaicism for sulfoiduronate sulfatase deficiency in carriers of Hunter's syndrome.
Capobianchi, MR; Romeo, G, 1976
)
0.26
" To study eventual rDNA variations in females aYbb chromosome was chosen since it can magnify in males but not show phenomena of rDNA dosage compensation."( Increase of rDNA redundancy in bb females of Drosophila melanogaster.
Gargano, S; Graziani, F, 1976
)
0.26
" However, the hibernating females of the low dosage group developed fewer lung tumors."( Carcinogenicity of N-nitrosodiethylamine in hibernating and nonhibernating European hamsters.
Mohr, U; Reznik, G; Reznik-Schüller, R, 1977
)
0.26
" Exogenous estrogen, administered in a second experiment at a dosage previously found to mimic the puberty-inducing action of a male, suppressed serum FSH and LH while elevating serum prolactin."( Differential effects of male stimuli on follicle-stimulating hormone, luteinizing hormone, and prolactin secretion in prepubertal female mice.
Bronson, FH; Maruniak, JA, 1976
)
0.26
" Each test drug was orally administered to 58 patients, in a daily dosage of 50 mg for 12 consecutive weeks."( [Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate. Part II: Self-assessment questionnaire method].
Kadono, M; Kato, S; Kumamoto, Y; Maki, A; Matsumoto, H; Mori, K; Sato, Y; Suzuki, R; Tanda, H; Yamaguchi, Y, 1990
)
0.28
" These age-related dispositional changes have led to age-dependent dosing recommendations."( The influence of endogenous and exogenous sex hormones in adolescents with attention to oral contraceptives and anabolic steroids.
Connor, JD; Lane, JR, 1994
)
0.29
"The nematode Caenorhabditis elegans counts its X chromosomes to determine sex and to activate the process of dosage compensation, which ensures that males (XO) and hermaphrodites (XX) express equal levels of most X-chromosome products."( Sex in the wormcounting and compensating X-chromosome dose.
Meyer, BJ, 2000
)
0.31
" Among HPV-positive women, dose-response relationships were observed for education, age at first intercourse and exposure to wood smoke that persisted after adjustment for previous screening."( Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras.
Bulnes, R; Claros, JM; de Barahona, O; Ferrera, A; Figueroa, M; Melchers, WJ; Toro, LA; Velema, JP, 2000
)
0.31
" Dosage compensation in birds appears to be phenotypically and molecularly quite different from X inactivation, being partial and gene-specific, but both systems use tools from the same molecular toolbox and there are some signs that galliform birds represent an early stage in the evolution of a coordinated system."( Avian sex, sex chromosomes, and dosage compensation in the age of genomics.
Graves, JA, 2014
)
0.4
" We use this framework to generate new comparative predictions for sexually antagonistic evolution in relation to dosage compensation, sex-specific mortality and assortative mating, revealing how molecular mechanisms, ecology and demography drive variation in masculinization versus feminization across the genome."( A gene's-eye view of sexual antagonism.
Gardner, A; Hitchcock, TJ, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency42.49860.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency13.08923.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.86000.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency10.58560.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency43.22890.000221.22318,912.5098AID1259247; AID743035; AID743042; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency19.12510.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.39120.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency2.90610.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency27.62380.003041.611522,387.1992AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.31120.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency52.47890.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency18.48900.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency10.31110.005428.02631,258.9301AID1346982
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency36.89030.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency36.89030.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.97420.023723.228263.5986AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency57.98340.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency5.21090.057821.109761.2679AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency28.06410.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency10.31110.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency10.31110.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency53.20870.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency2.96450.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.05480.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7,118)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905356 (75.25)18.7374
1990's748 (10.51)18.2507
2000's607 (8.53)29.6817
2010's317 (4.45)24.3611
2020's90 (1.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.11 (24.57)
Research Supply Index8.96 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index37.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials58 (0.75%)5.53%
Reviews402 (5.19%)6.00%
Case Studies160 (2.07%)4.05%
Observational3 (0.04%)0.25%
Other7,120 (91.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]